Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

NCT02162550 · Unknown status

Last updated 2026-05-28

This clinical trial tested whether Bydureon, a medication for type 2 diabetes, affects the progression of plaque buildup in the carotid arteries of adults with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 148 people Planned (estimated).

Who can join Ages 21–75 · all sexes

Timeline Started 2014-06 · est. completion 2019-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02162550 ↗

Description as written by the study sponsor.

Investigators will be determining whether a once weekly injectable medication Bydureon versus placebo is able to reduce the development of atherosclerosis. Investigators are testing the overall hypothesis that 18 months of Bydureon treatment will improve cardiovascular risk factors, endothelial function and retard carotid atherosclerosis plaque progression in type 2 diabetes mellitus (T2DM). Investigators anticipate these studies will provide novel information about the temporal relationship between Bydureon induced changes in risk factors, endothelial function and atherosclerosis progression.

Treatments tested

Bydureon also known as long-acting exenatide Drug

once weekly injection
placebo also known as inactive agent Drug

once weekly injection

Main thing measured	Change in carotid plaque volume
Sponsor	Phoenix VA Health Care System
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02162550 ↗